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A BS TR AC T
BACKGROUND
Subthalamic stimulation reduces motor disability and improves quality of life in 
patients with advanced Parkinson’s disease who have severe levodopa-induced motor 
complications. We hypothesized that neurostimulation would be beneficial at an 
earlier stage of Parkinson’s disease.
METHODS
In this 2-year trial, we randomly assigned 251 patients with Parkinson’s disease and 
early motor complications (mean age, 52 years; mean duration of disease, 7.5 years) 
to undergo neurostimulation plus medical therapy or medical therapy alone. The 
primary end point was quality of life, as assessed with the use of the Parkinson’s 
Disease Questionnaire (PDQ-39) summary index (with scores ranging from 0 to 100 
and higher scores indicating worse function). Major secondary outcomes included 
parkinsonian motor disability, activities of daily living, levodopa-induced motor com-
plications (as assessed with the use of the Unified Parkinson’s Disease Rating Scale, 
parts III, II, and IV, respectively), and time with good mobility and no dyskinesia.
RESULTS
For the primary outcome of quality of life, the mean score for the neurostimulation 
group improved by 7.8 points, and that for the medical-therapy group worsened by 
0.2 points (between-group difference in mean change from baseline to 2 years, 8.0 
points; P = 0.002). Neurostimulation was superior to medical therapy with respect 
to motor disability (P<0.001), activities of daily living (P<0.001), levodopa-induced 
motor complications (P<0.001), and time with good mobility and no dyskinesia 
(P = 0.01). Serious adverse events occurred in 54.8% of the patients in the neuro-
stimulation group and in 44.1% of those in the medical-therapy group. Serious 
adverse events related to surgical implantation or the neurostimulation device oc-
curred in 17.7% of patients. An expert panel confirmed that medical therapy was 
consistent with practice guidelines for 96.8% of the patients in the neurostimula-
tion group and for 94.5% of those in the medical-therapy group.
CONCLUSIONS
Subthalamic stimulation was superior to medical therapy in patients with Parkinson’s 
disease and early motor complications. (Funded by the German Ministry of Research 
and others; EARLYSTIM ClinicalTrials.gov number, NCT00354133.)
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Parkinson’s disease is a progressive neurodegenerative disease that affects do-paminergic neurotransmission, resulting in 
bradykinesia, rigidity, and rest tremor. After an 
initial honeymoon period, during which there is 
a sustained response to dopaminergic treatment, 
beneficial effects are hampered by levodopa- 
induced motor complications,1 progressively com-
promising quality of life.2-4
Because levodopa-responsive parkinsonian 
symptoms are improved by high-frequency stim-
ulation of the subthalamic nucleus,5,6 neuro-
stimulation has become an established treatment 
for advanced Parkinson’s disease with medically 
intractable fluctuations and dyskinesia7-10 and 
has shown long-term efficacy.11-13 It is typically 
used after the disease has been present for 11 to 
13 years,7-10 when quality of life, social adjust-
ment (psychosocial competence),14 and profes-
sional activity are already severely impaired. 
Neurostimulation improves quality of life,7-10 in 
addition to motor symptoms. Moreover, later in 
the course of the disease, features unresponsive 
to dopaminergic treatment often predominate. 
Therefore, optimizing quality of life during the 
period when patients have the greatest response 
to dopaminergic therapy (and therefore neuro-
stimulation as well) should be considered a major 
goal of current treatment. We hypothesized that 
neurostimulation improves quality of life at an 
earlier stage of Parkinson’s disease, as suggested 
by our pilot trial involving patients with early and 
mild motor complications.15
In the current study, we randomly assigned 
patients with Parkinson’s disease and a recent 
onset of motor complications to receive neuro-
stimulation plus medical therapy or medical 
therapy only. Disease-related quality of life was 
chosen as the primary outcome, thereby allowing 
a global assessment of beneficial and adverse 
effects in a way that subjectively matters to the 
patient.
ME THODS
PATIENTS
Patients with Parkinson’s disease were eligible 
for the study if they met the following inclusion 
criteria: an age of 18 to 60 years; disease duration 
of 4 years or more; a disease severity rating below 
stage 3 in the on-medication condition, accord-
ing to the Hoehn and Yahr scale, with scores 
ranging from 0 to 5 and higher scores indicating 
more severe disease16; improvement of motor signs 
of 50% or more with dopaminergic medication,6 
as assessed with the use of the Unified Parkin-
son’s Disease Rating Scale, part III (UPDRS-III; 
scores range from 0 to 108, with higher scores 
indicating worse functioning)17; fluctuations or 
dyskinesia present for 3 years or less; and a score 
of more than 6 for activities of daily living in the 
worst condition despite medical treatment, as as-
sessed with the use of the UPDRS-II (scores range 
from 0 to 52, with higher scores indicating worse 
functioning), or mild-to-moderate impairment 
in social and occupational functioning (score of 
51 to 80% on the Social and Occupational Func-
tioning Assessment Scale,18 with scores ranging 
from 1 to 100 and lower scores indicating worse 
functioning).
Exclusion criteria were dementia (a score of 
≤130 on the Mattis Dementia Rating Scale,19 
with scores ranging from 0 to 144 and higher 
scores indicating better functioning), major de-
pression with suicidal thoughts (a score of >25 on 
the Beck Depression Inventory II,20 with scores 
ranging from 0 to 63 and higher scores indicat-
ing worse functioning), acute psychosis, and any 
medical or psychological problem that would in-
terfere with the conduction of the study protocol.21 
Patients with a duration of disease of less than 
4 years were excluded because atypical forms of 
parkinsonism would be expected to be identifi-
able before then. Details regarding the scales are 
provided in Tables S1, S2, and S3 in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
STUDY DESIGN
Conducted in Germany and France, this study 
followed an investigator-initiated, randomized, 
multicenter, parallel-group design comparing 
neurostimulation plus medical therapy (neuro-
stimulation group) with medical therapy alone 
(medical-therapy group). Randomization was 
performed centrally at the University of Marburg 
coordinating center, Marburg, Germany, with the 
use of randomization lists with randomly permut-
ed block lengths stratified according to center.
The trial conformed to the Declaration of Hel-
sinki, Good Clinical Practice guidelines, and the 
International Organization for Standardization 
14:155 (2003) standards and was approved by the 
ethics committee for each participating center. 
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All patients provided written informed consent 
before randomization. An independent data and 
safety monitoring committee provided review and 
direction regarding the collection of safety data.
Full source-data verification was performed by 
monitors from the German coordinating center 
(Koordinierungszentrum für Klinische Studien) 
for the German centers and by monitors from the 
French coordinating center (Department of Clin-
ical Research, Assistance Publique–Hôpitaux de 
Paris) for the French centers. Data were collected 
and analyzed by the German coordinating center 
in Marburg. All the authors vouch for the accu-
racy of the data and the analyses reported and 
for the adherence of the study to the protocol, 
available at NEJM.org. The protocol committee 
designed the study, and the steering committee 
wrote the first draft of the manuscript. Medtron-
ic provided additional funding for the study but 
had no role in the study design, data accrual, 
data analysis, or manuscript preparation.
Patients assigned to neurostimulation under-
went bilateral stereotactic surgery of the subtha-
lamic nucleus with the implantation of electrodes 
(model 3389, Medtronic) and a pulse generator 
(Kinetra or Soletra, Medtronic) within 6 weeks 
after randomization, according to operative stan-
dards that address local anesthesia, imaging, tar-
geting, microelectrode recording, and confirma-
tion of the final electrode position.21 Patients in 
the neurostimulation group then began receiving 
stimulation according to standards established for 
this study (see the Supplementary Appendix).21
Assessments were scheduled at baseline and at 
5, 12, and 24 months. A levodopa challenge test 
was performed at baseline and at 24 months (see 
the Supplementary Appendix).21 Blinded assess-
ments were based on preoperative and postop-
erative standardized video recordings obtained 
at baseline and at 24 months. Videos were re-
corded for each motor condition (according to 
whether the patient was or was not receiving 
medication or stimulation). The UPDRS-III score 
was assessed by two expert raters who were un-
aware of the study assignments,22 except for the 
assessment of rigidity, which cannot be evaluated 
on the basis of a video recording.
During follow-up, adjustments to medication 
and stimulation were performed according to pre-
defined standards.21 These standards followed the 
European Federation of Neurological Societies 
guidelines for the treatment of advanced Parkin-
son’s disease23 and a standardized sequence of 
interventions.21 An independent expert panel as-
sessed whether medication therapy was consis-
tent with guidelines for each patient (see the 
Supplementary Appendix).
A specific procedure for monitoring the risk 
of suicidality, established after two suicides had 
occurred during the study, consisted of a baseline 
assessment of the general risk and a semistruc-
tured telephone interview every 2 months to as-
sess status, with psychiatric follow-up as needed 
(see the Supplementary Appendix).21
OUTCOME MEASURES
The primary end point was the between-group 
difference in mean change in quality of life from 
baseline to 2 years, as assessed with the use of 
the summary index of the Parkinson’s Disease 
Questionnaire (PDQ-39).24,25 After we obtained a 
significant result for quality of life, the following 
clinically relevant motor functions were tested 
sequentially as major secondary outcomes: ac-
tivities of daily living (UPDRS-II score),17 severity 
of motor signs (UPDRS-III score), severity of 
treatment-related complications (UPDRS-IV score), 
and time with good mobility and no troublesome 
dyskinesia, as recorded by patients in a diary. Mi-
nor secondary outcomes included scores on the 
Scales for Outcomes in Parkinson’s Disease–Psy-
chosocial (SCOPA-PS) questionnaire (on a scale 
from 0 to 33, with higher scores indicating worse 
functioning), the Mattis Dementia Rating Scale19 
(on a scale of 0 to 144, with higher scores indicat-
ing better functioning), the Brief Psychiatric Rating 
Scale26 (on a scale of 18 to 126, with higher 
scores indicating worse functioning), the Mont-
gomery and Åsberg Depression Rating Scale27 (on 
a scale of 0 to 60, with higher scores indicating 
worse functioning), the Beck Depression Inven-
tory II20 (on a scale of 0 to 63, with higher scores 
indicating worse functioning), and the Starkstein 
Apathy Scale28 (on a scale of 0 to 42, with higher 
scores indicating worse functioning), as well as 
the levodopa-equivalent daily dose.7,9,21,29 The 
other minor secondary outcomes are listed in the 
Supplementary Appendix.
ADVERSE EVENTS
Adverse events in all patients were reported and 
coded according to the Medical Dictionary for Regu-
latory Activities, version 14.1. Serious adverse 
events were defined as any events that led to 
death, disability, or prolonged or new hospital-
ization with serious health impairment.
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STATISTICAL ANALYSIS
The sample size was calculated on the basis of 
our previous studies.7,15 We selected a power of 
80% for a two-sided Mann–Whitney test, assum-
ing normally distributed data. To detect a stan-
dardized effect size of 0.4 with an alpha level of 
5%, we calculated that we would need to enroll 
208 patients. Assuming a 15% rate of loss to 
follow-up, we determined that a total enrollment 
of at least 246 patients would be required. The 
intention-to-treat analysis was primary; the per-
protocol analysis was secondary. No interim 
analysis was planned. The Mann–Whitney test 
was replaced by a flexible and robust linear 
mixed-model analysis with baseline adjustment 
and included study center as a random effect, 
main effects for group and time, a group-by-time 
interaction term, and a generalized covariance 
matrix to account for serial dependency among 
observations after verification of the assumption 
of multivariate normality for the parametric 
model.21 Differences in mean changes between 
assessments at baseline and at 24 months were 
compared between the groups. Missing data due 
to loss to follow-up were handled by means of 
direct likelihood analyses,30,31 with adjustment 
for the conditional expectation of the missing 
measurements, given the observed ones.
A serial gatekeeper procedure was planned. If 
the primary end point was significant, the UPDRS-
II, UPDRS-III, and UPDRS-IV scores and time with 
good mobility and no troublesome dyskinesia 
were tested sequentially with the use of Hoch-
berg’s multiple-comparison method32 at a sig-
nificance level of 5%.
R ESULT S
CHARACTERISTICS OF THE PATIENTS
Of 392 patients assessed for eligibility, 251 were 
enrolled between July 2006 and November 2009 
at nine German and eight French university cen-
ters (Fig. S1 in the Supplementary Appendix). 
The intention-to-treat population consisted of 
124 patients assigned to the neurostimulation 
group (120 of whom underwent implantation and 
completed the study) and 127 patients assigned to 
the medical-therapy group (of whom 125 under-
went medical therapy and 123 completed the study). 
A total of 25 patients had major protocol devia-
tions, including PDQ-39 assessment outside the 
predefined time window, an absence of motor 
fluctuations or dyskinesia, insufficient exposure 
to treatment, and death during the study period. 
The per-protocol analysis included 116 patients 
in the neurostimulation group and 110 in the 
medical-therapy group (Fig. S1 in the Supple-
mentary Appendix). Baseline characteristics did 
not differ significantly between the treatment 
groups (Table 1). The mean duration of Parkin-
son’s disease was 7.5 years, and patients were 
included in the study a mean of 1.7 years after 
the onset of levodopa-induced motor complica-
tions of any severity.
QUALITY-OF-LIFE, ACTIVITIES OF DAILY LIVING,  
AND MOTOR OUTCOMES
The primary outcome (PDQ-39 summary index 
score) was improved from baseline to 24 months by 
26% in the neurostimulation group but worsened 
by 1% in the medical-therapy group (Table 2). In 
the intention-to-treat population, the between-
group difference in the mean change from base-
line was 8.0 points (P = 0.002), which was similar 
to the between-group differences in the per-pro-
tocol population and the group of patients who 
completed the PDQ-39 assessment. The maximum 
Table 1. Baseline Characteristics of the Study Population.*
Characteristic
Neurostimulation 
(N = 124)
Medical Therapy 
(N = 127)
Age — yr 52.9±6.6 52.2±6.1
Sex — no. (%)
Male 94 (75.8) 85 (66.9)
Female 30 (24.2) 42 (33.1)
Duration of Parkinson’s disease — yr 7.3±3.1 7.7±2.7
Dyskinesia†
No. of patients 84 94
Duration — yr 1.4±0.8 1.5±0.8
Motor fluctuations†
No. of patients 121 124
Duration — yr 1.6±0.8 1.8±0.8
Treatment with levodopa
No. of patients 111 115
Duration — yr 4.8±3.3 5.0±3.3
Treatment with dopamine agonist
No. of patients 118 115
Duration — yr 5.9±3.0 6.1±3.0
Levodopa-equivalent daily dose — mg 918.8±412.5 966.9±416.5
* Plus–minus values are means ±SD. There were no significant between-group 
differences.
† The presence of dyskinesias or fluctuations for 3 years or less was an eligibility 
criterion.
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effect was reached at 5 months and remained 
stable for up to 24 months (Fig. 1A). Scores in all 
domains of the PDQ-39 except for communica-
tion and social support showed significant im-
provement in favor of neurostimulation (Fig. 1B). 
The SCOPA-PS score for psychosocial perfor-
mance was also significantly better in the neuro-
stimulation group than in the medical-therapy 
group (P = 0.02). These changes were confirmed 
by further testing with the use of generic and 
disease-specific quality-of-life and disability scales 
(Table S3 in the Supplementary Appendix).
UPDRS-III scores for the severity of parkinso-
nian motor signs in the off-medication condition 
(with assessments conducted after medications 
had been withheld for ≥12 hours) improved by 
53% in the neurostimulation group; the between-
group difference in mean change at 2 years was 
16.4 points in favor of neurostimulation (P<0.001). 
This finding was confirmed by means of blinded 
assessment of the video recordings of the UPDRS-
III score, corroborating the significant improve-
ment among patients in the neurostimulation 
group, as compared with the medical-therapy 
group, in which scores did not change (P<0.001) 
(Table 2). A smaller but significant benefit was 
observed for patients in the neurostimulation 
group in the on-medication and on-stimulation 
condition (Table 2). UPDRS-IV scores for levodopa-
induced complications, including motor fluctua-
tions and dyskinesia, improved by 61% in the 
neurostimulation group, with a 4.1-point differ-
ence between treatment groups (P<0.001) (Table 
2), which was confirmed by the scores on a dys-
kinesia scale (Table S3 in the Supplementary 
Appendix).
UPDRS-II scores for activities of daily living in 
the worst condition during the preceding week 
differed by 6.2 points in favor of neurostimula-
tion (P<0.001) (Table 2), with no significant be-
tween-group difference for the score in the best 
condition. Time with good mobility and no 
troublesome dyskinesia, as recorded by the pa-
tients in daily diaries, increased by 20% in the 
neurostimulation group, with a between-group 
difference of 1.9 hours (P = 0.01) (Table 2). Time 
with bad mobility was significantly shortened in 
the neurostimulation group, with a between-
group difference of 1.8 hours (P = 0.006) (Table 
S3 in the Supplementary Appendix). Between-
group differences in time with troublesome 
dyskinesia and sleep time (Fig. S2 in the Supple-
mentary Appendix) were not significant.
Medication use was significantly changed in 
both treatment groups. The levodopa-equivalent 
daily dose was reduced by 39% in the neuro-
stimulation group but was increased by 21% in 
the medical-therapy group, with a between-group 
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Figure 1. Quality of Life as Assessed by Means of the Parkinson’s Disease 
Questionnaire (PDQ-39).
Panel A shows scores on the summary index of the PDQ-39 at baseline and 
at 5, 12, and 24 months for both treatment groups. Scores range from 0 to 
100, with lower values indicating better quality of life. Panel B shows the 
change in the subscores for the various domains of the PDQ-39. Positive 
values indicate improvement.
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difference of 609 mg (P<0.001) (Table 2, and 
Table S3 in the Supplementary Appendix).
COGNITIVE AND EMOTIONAL OUTCOMES
No significant between-group differences were 
observed for cognitive assessments obtained with 
the use of the Mattis Dementia Rating Scale or 
the UPDRS-I (Table 2). Changes in mood, as rated 
by the examiner (score on the Montgomery and 
Åsberg Depression Rating Scale) or by patients 
(score on the Beck Depression Inventory II), were 
in favor of neurostimulation, as were the scores 
on the Brief Psychiatric Rating Scale for overall 
psychiatric morbidity. Scores on the Starkstein 
Apathy Scale worsened in both treatment groups, 
with a nonsignificant trend toward worse ratings 
for apathy among patients in the neurostimula-
tion group than among those in the medical-
therapy group (Table 2).
ADVERSE EVENTS
A total of 68 patients in the neurostimulation 
group and 56 in the medical-therapy group had 
at least one serious adverse event. Numbers of all 
adverse events were similar in the two groups 
(Table 3, and Table S4 in the Supplementary Ap-
pendix). Two patients in the neurostimulation 
group and 1 in the medical-therapy group com-
mitted suicide; these were the only deaths. Sui-
cidal ideation and suicide attempts were of simi-
lar frequency in the two groups, but depression 
was more frequent in the neurostimulation group. 
Serious adverse events related to motor prob-
lems, impulse control disorders, and psychotic 
manifestations were more common in the medi-
cal-therapy group. Of 26 serious adverse events 
related to surgery or the implanted device, includ-
ing a brain abscess and a case of unspecific ede-
ma, all but 1 resolved completely; the exception 
was a case of impaired wound healing, which 
resulted in mild scarring. Unscheduled visits were 
offered for all health problems; 343 visits oc-
curred in the medical-therapy group and 277 in 
the neurostimulation group.
ASSESSED CONSISTENCY OF TREATMENT  
WITH GUIDELINES
Experts assessed medical therapy as consistent 
with guidelines in 120 patients (96.8%) in the 
neurostimulation group and in 120 patients 
(94.5%) in the medical-therapy group. Stimula-
tion parameters at 24 months were similar for 
both hemispheres, with a mean (±SD) stimula-
tion strength of 2.8±0.7 V, a mean stimulation 
frequency of 142±27 Hz, and a mean pulse dura-
tion of 66±13 μs (pooled data).
DISCUSSION
This patient population with relatively mild par-
kinsonian motor signs differed from the popula-
tions in previous controlled studies of neuro-
stimulation: the mean duration of disease in the 
patients in our study was only 7.5 years, as com-
pared with 11.1 to 13.8 years7-10; patients were 
younger (52 years, as compared with 59 to 62 
years8-11); and fluctuations and dyskinesia were 
present for only 1.7 and 1.5 years, respectively. 
Nevertheless, patients in the neurostimulation 
group had a 26% improvement in the PDQ-39 
summary index score, corroborating the 24% im-
provement observed in our pilot study15 and the 
25% improvement observed in our large trial in-
volving patients with advanced Parkinson’s dis-
ease,7 in both of which the PDQ-39 summary 
index score was the primary outcome. The be-
tween-group difference in the mean change from 
baseline of 8.0 points for the PDQ-39 summary 
index score in favor of neurostimulation is a clin-
ically relevant finding.33-35 The profile of im-
provement in subdomains of quality of life dif-
fered slightly from that among patients treated at 
an advanced stage of the disease,7 because activ-
ity of daily living, emotional well-being, and cog-
nition improved more during this study than 
during prior studies involving patients with ad-
vanced Parkinson’s disease. The improvement in 
the primary outcome was consistent with other 
measures of quality of life, psychiatric morbidity, 
and psychosocial function, which all improved in 
the neurostimulation group, as compared with 
the medical-therapy group.
Patients received neurostimulation at a stage 
of the disease when medical treatment is still ef-
fective for motor function, as reflected by several 
findings in the medical-therapy group: the ab-
sence of a significant change from baseline in the 
UPDRS-III motor score and only minimal wors-
ening in the UPDRS-II score for activities of daily 
living and in the UPDRS-IV score for levodopa-
induced complications. In addition, diary results 
for mobility did not change significantly from 
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baseline in the medical-therapy group, but time 
with bad mobility was reduced and time with 
good mobility was significantly increased in the 
neurostimulation group. The observed difference 
between the treatment groups is thus due to an 
improvement among patients receiving neuro-
stimulation, as compared with those receiving 
medical therapy alone, not to deterioration among 
the latter patients.
Neurostimulation in combination with medi-
cal therapy can therefore improve motor symp-
toms better than medical therapy alone at this 
earlier stage. Because the levodopa response 
predicts the extent of the effect of subthalamic 
stimulation on parkinsonian motor signs, the 
improvement of the off-medication condition 
with the use of stimulation was expected. More-
over, in spite of a ceiling effect, the combination 
of stimulation and medication resulted in a 
small but significant improvement in the motor 
score, as compared with medical treatment alone. 
As a main benefit from the patient’s perspective, 
activities of daily living were improved among 
patients with neurostimulation in the worst con-
dition during the day, although, as expected, there 
was no significant difference between groups in 
the best condition.
Overall, adverse events were more frequent 
among patients receiving neurostimulation than 
among those receiving medical therapy only. 
However, this result was mainly due to a higher 
number of mild adverse events in the neurostimu-
lation group than in the medical-therapy group. 
Serious adverse events in the medical-therapy 
Table 3. Adverse Events.*
Event Neurostimulation (N = 124) Medical Therapy (N = 127)
no. of  
events
no. of patients  
with event (%)
no. of  
events
no. of patients  
with event (%)
Serious adverse events 123 68 (54.8) 128 56 (44.1)
Death, all by suicide 2 2 (1.6) 1 1 (0.8)
Life-threatening event 14 12 (9.7) 17 9 (7.1)
Event related to medication or stimulation 24 24 (19.4) 52 38 (29.9)
Worsening of mobility† 5 5 (4.0) 13 11 (8.7)
Motor fluctuations 0 0 7 7 (5.5)
Dyskinesia 1 1 (0.8) 2 2 (1.6)
Psychosis or hallucinations 0 0 8 6 (4.7)
Anxiety 0 0 3 2 (1.6)
Impulse control disorder 1 1 (0.8) 5 5 (3.9)
Depression 6 6 (4.8) 3 1 (0.8)
Suicidal ideation 1 1 (0.8) 0 0
Suicide attempt 2 2 (1.6) 2 2 (1.6)
Cardiac disorder 0 0 2 2 (1.6)
Injury 3 3 (2.4) 0 0
Respiratory or thoracic disorder 1 1 (0.8) 0 0
Other 4 4 (3.2) 7 5 (3.9)
Event related to surgery or device 26 22 (17.7) — —
Impaired wound healing 4 4 (3.2) — —
Intracerebral abscess or edema 2 2 (1.6) — —
Dislocation of device‡ 5 4 (3.2) — —
Reoperation necessary§ 4 2 (1.6) — —
Other 11 10 (8.1) — —
Event related to Parkinson’s disease 57 39 (31.5) 58 31 (24.4)
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group were more often related to problems of 
mobility and side effects of medications (hallu-
cinations and behavioral problems), whereas ma-
jor depression occurred more often among pa-
tients with neurostimulation, despite an overall 
improvement in mood at the end of the trial. The 
frequency of suicidal behavior, including suicide, 
was high36 but did not differ between treatment 
groups. Although there were three suicides (two 
in the neurostimulation group and one in the 
medical-therapy group) as well as four suicide 
attempts (two in the neurostimulation group and 
two in the medical-therapy group) during the 
study, this trial did not suggest that neurostimu-
lation is associated with a higher risk of suicide 
than medical therapy. Instead, we hypothesize 
that the decision to eventually undergo neuro-
stimulation may select a specific subgroup of 
patients with a higher risk for suicidal behavior 
than the general population. The monitoring 
procedures established in this study may be use-
ful in the future. A total of 26 serious adverse 
events were related directly to surgery or the 
implanted devices; 25 of them resolved com-
pletely, and 1 left a cutaneous scar.
The strengths of this study include the strict 
standards for interventions, close monitoring of 
side effects, the small number of withdrawals, 
and the consistency between the results of the 
intention-to-treat and per-protocol analyses. Be-
cause standards of medical therapy were well 
respected in both treatment groups and because 
motor symptoms and quality of life did not change 
in the medical-therapy group, the improvement 
Table 3. (Continued.)
Event Neurostimulation (N = 124) Medical Therapy (N = 127)
no. of  
events
no. of patients  
with event (%)
no. of  
events
no. of patients  
with event (%)
Adverse events¶ 1032 121 (97.6) 925 125 (98.4)
Mild 636 105 (84.7) 435 100 (78.7)
Moderate 364 95 (76.6) 437 98 (77.2)
Severe 32 20 (16.1) 53 35 (27.6)
Moderate or severe‖
Dyskinesia 24 18 (14.5) 69 49 (38.6)
Gait disorder 25 17 (13.7) 25 15 (11.8)
Worsening of mobility 74 40 (32.3) 137 72 (56.7)
Depression 27 21 (16.9) 32 23 (18.1)
Sleep disorder 17 14 (11.3) 19 16 (12.6)
Impulse control disorder 26 18 (14.5) 23 15 (11.8)
Musculoskeletal or connective tissue disorder 14 13 (10.5) 14 11 (8.7)
Pain 30 19 (15.3) 15 12 (9.4)
Weight change 15 15 (12.1) 6 6 (4.7)
* All adverse events are listed according to the Medical Dictionary for Regulatory Activities, version 14.1.
† Worsening of mobility was defined as tremor, rigidity, akinesia, wearing off of medication effect, dystonia, or worsening 
of symptoms of Parkinson’s disease.
‡ Dislocation of device was defined as the dislocation of the stimulator, cable, or lead.
§  Reoperation was necessary in order to repair the stimulator or lead.
¶ All nonserious adverse events are listed.
‖ Data include moderate, severe, or life-threatening adverse events that were not serious and were reported in at least 10% 
of the patients in at least one group. These latter adverse events were judged to be life-threatening by the investigator but 
did not fulfill the criteria for seriousness, which include hospitalization, prolongation of hospitalization, or death. There 
were nonlethal life-threatening adverse events that did not lead to hospitalization. The remaining moderate, severe, and 
life-threatening events are reported in detail in Table S4 in the Supplementary Appen dix. A moderate adverse event was de-
fined as one that might interfere with normal activity and lead to the consideration of medical intervention or close follow-
up, and a severe adverse event as an event posing a substantial risk to the patient’s health and likely to require medical in-
tervention or close follow-up. Severe adverse events reported here included two life-threatening adverse events that were 
not judged to fulfill the criteria for seriousness.
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among patients who underwent surgical implan-
tation can be attributed to neurostimulation. To 
overcome the difficulties of blinding in neuro-
stimulation studies,21 we introduced the blinded 
review of motor scores with the use of video 
recordings, which confirmed the superior effect 
of neurostimulation over medical therapy, sup-
porting the validity of the main study result.
In conclusion, we found that neurostimulation 
was superior to medical therapy alone at a rela-
tively early stage of Parkinson’s disease, before 
the appearance of severe disabling motor com-
plications. Neurostimulation may be a therapeu-
tic option for patients at an earlier stage than 
current recommendations suggest.23,37
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